Implementation of rapid COVID-19 testing at Massachusetts trial courts.

COVID-19 testing Criminal-legal Justice-involved Trial court

Journal

Health & justice
ISSN: 2194-7899
Titre abrégé: Health Justice
Pays: England
ID NLM: 101626355

Informations de publication

Date de publication:
10 Apr 2023
Historique:
received: 12 07 2022
accepted: 22 03 2023
medline: 11 4 2023
entrez: 10 4 2023
pubmed: 11 4 2023
Statut: epublish

Résumé

COVID-19 shut down trial courts across the country, prolonging case resolution of charged, detained, and incarcerated people. We report on the implementation of rapid COVID-19 testing at Trial Courts in Massachusetts (MA), focusing on the outcomes of adoption and acceptability. Guided by the Expert Recommendations in Implementing Change (ERIC) framework, we chose six strategies to guide implementation. After assembling a group of stakeholders, including representatives of the Trial Court, Department of Public Health (DPH) and vendors providing COVID-19 testing, we implemented rapid COVID-19 testing at Trial Court locations in December 2021. We collected data on (1) adoption of COVID-19 testing, (2) number of stakeholders who attended meetings, (3) number of tests performed at Trial Court sites, and (4) acceptability of COVID-19 testing using a QR-code anonymous survey. There was a high percentage of attendance at stakeholder meetings (> 70% at each meeting). 243 COVID-19 tests were conducted on eight occasions at four Trial Court sites between December 2021 and February 2022. Participants who responded to the QR-code survey reflected favorably on COVID-19 testing at MA Trial Court sites. COVID-19 testing at Massachusetts Trial Court sites was possible through stakeholder engagement. Several cases of COVID-19 were identified prior to entry into the Trial Court. Funding for rapid COVID-19 testing should be provided to help keep trial courts open as the pandemic continues to evolve.

Sections du résumé

BACKGROUND BACKGROUND
COVID-19 shut down trial courts across the country, prolonging case resolution of charged, detained, and incarcerated people. We report on the implementation of rapid COVID-19 testing at Trial Courts in Massachusetts (MA), focusing on the outcomes of adoption and acceptability.
METHODS METHODS
Guided by the Expert Recommendations in Implementing Change (ERIC) framework, we chose six strategies to guide implementation. After assembling a group of stakeholders, including representatives of the Trial Court, Department of Public Health (DPH) and vendors providing COVID-19 testing, we implemented rapid COVID-19 testing at Trial Court locations in December 2021. We collected data on (1) adoption of COVID-19 testing, (2) number of stakeholders who attended meetings, (3) number of tests performed at Trial Court sites, and (4) acceptability of COVID-19 testing using a QR-code anonymous survey.
RESULTS RESULTS
There was a high percentage of attendance at stakeholder meetings (> 70% at each meeting). 243 COVID-19 tests were conducted on eight occasions at four Trial Court sites between December 2021 and February 2022. Participants who responded to the QR-code survey reflected favorably on COVID-19 testing at MA Trial Court sites.
CONCLUSION CONCLUSIONS
COVID-19 testing at Massachusetts Trial Court sites was possible through stakeholder engagement. Several cases of COVID-19 were identified prior to entry into the Trial Court. Funding for rapid COVID-19 testing should be provided to help keep trial courts open as the pandemic continues to evolve.

Identifiants

pubmed: 37036544
doi: 10.1186/s40352-023-00220-1
pii: 10.1186/s40352-023-00220-1
pmc: PMC10084651
doi:

Types de publication

Journal Article

Langues

eng

Pagination

21

Subventions

Organisme : National Institute for Health Care Management Foundation
ID : 3UG-DA050072
Organisme : NIEHS NIH HHS
ID : K08HS026008-01A
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Law Hum Behav. 2021 Apr;45(2):81-96
pubmed: 34110871
Public Health Rep. 2022 May-Jun;137(3):442-448
pubmed: 35184638
Clin Infect Dis. 2020 Jul 28;71(15):891-892
pubmed: 32221515
Pediatrics. 2022 Feb 1;149(12 Suppl 2):
pubmed: 34737173
N Engl J Med. 2022 Jan 20;386(3):264-272
pubmed: 34995029
N Engl J Med. 2021 Apr 29;384(17):1583-1585
pubmed: 33657290
Am J Crim Justice. 2020;45(4):743-758
pubmed: 32837170
Inquiry. 2021 Jan-Dec;58:469580211060750
pubmed: 34845941
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199
Pediatrics. 2022 May 1;149(5):
pubmed: 35132435
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1349-1354
pubmed: 34555009
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
J Clin Virol Plus. 2021 Jun;1(1):100019
pubmed: 35262006
Implement Sci. 2013 Dec 01;8:139
pubmed: 24289295
BMC Public Health. 2022 May 14;22(1):977
pubmed: 35568894
Implement Sci. 2022 Jan 22;17(1):7
pubmed: 35065675
JAMA Intern Med. 2020 Aug 1;180(8):1041-1042
pubmed: 32343355

Auteurs

Yvane Ngassa (Y)

Department of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA. yvane.ngassa@tuftsmedicine.org.

Emma Smyth (E)

Department of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA.

Bridget Pickard (B)

Department of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA.

Morgan Maner (M)

Brody School of Medicine, Eastern Carolina University, Greenville, NC, USA.

Lauren Brinkley Rubinstein (LB)

Department of Population Health Sciences, Duke University, Durham, NC, USA.

Alysse Wurcel (A)

Department of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, 15 Kneeland St, Boston, MA, 02111, USA.

Classifications MeSH